Brand P L, Kerstjens H A, Postma D S, Sterk P J, Quanjer P H, Sluiter H J, Dijkman J H, van Herwaarden C L, Hilvering C, Jansen H M
Dept of Pulmonology, University Hospital, Groningen, The Netherlands.
Eur Respir J. 1992 Jan;5(1):21-31.
Airways obstruction and airways hyperresponsiveness are two dominant features in patients with chronic nonspecific lung disease (asthma and chronic obstructive pulmonary disease (COPD)). We set up a study to determine whether long-term (3 yrs) therapeutic intervention directed at airways obstruction and hyperresponsiveness is superior to one directed at airways obstruction alone. Patients were selected on functional criteria (age, baseline forced expiratory volume in one second (FEV1), and airways hyperresponsiveness) and, furthermore, extensively characterized by history, smoking habits, allergy, reversibility of airways obstruction and quality of life. The methodology and practical problems of setting up this large multicentre study are outlined, together with an analysis of baseline data. Standardization of methods and techniques and recruitment of patients required much effort, recruitment taking about twice as long as expected. A 3 month feasibility study allowed us to eliminate minor problems in the protocol. Over a 16 month period, 274 adult patients (18-60 yrs) from the out-patient clinics of six university centres entered the study; 99 met the diagnostic criteria for asthma, 51 for COPD, 88 for asthmatic bronchitis, and 36 could not be classified. Their mean (SD) FEV1% pred was 65.1 (15.2)%. Their geometric mean provoking concentration of histamine producing a 20% fall in FEV1 (PC20 histamine) was 0.28 mg.ml-1. In a multiple regression analysis, more severe airways hyperresponsiveness was associated with lower prechallenge FEV1% pred (p less than 0.0001), higher pack-years of smoking (p = 0.0099), blood eosinophil count (p = 0.0004), skin test reactivity (p = 0.0047) and with female sex (p = 0.0302). We conclude that setting up long-term multicentre trials in chronic nonspecific lung disease (CNSLD) is feasible and that these may offer valuable information on treatment and outcome of the disease.
气道阻塞和气道高反应性是慢性非特异性肺部疾病(哮喘和慢性阻塞性肺疾病(COPD))患者的两个主要特征。我们开展了一项研究,以确定针对气道阻塞和高反应性的长期(3年)治疗干预是否优于仅针对气道阻塞的干预。根据功能标准(年龄、基线一秒用力呼气容积(FEV1)和气道高反应性)选择患者,此外,还通过病史、吸烟习惯、过敏、气道阻塞的可逆性和生活质量进行了广泛的特征描述。概述了开展这项大型多中心研究的方法和实际问题,并对基线数据进行了分析。方法和技术的标准化以及患者的招募需要付出很大努力,招募时间大约是预期的两倍。一项为期3个月的可行性研究使我们能够消除方案中的小问题。在16个月的时间里,来自六个大学中心门诊的274名成年患者(18 - 60岁)进入了研究;99名符合哮喘诊断标准,51名符合COPD诊断标准,88名符合喘息性支气管炎诊断标准,36名无法分类。他们的平均(标准差)FEV1%预计值为65.1(15.2)%。引起FEV1下降20%的组胺激发浓度几何均值(PC20组胺)为0.28mg.ml-1。在多元回归分析中,更严重的气道高反应性与较低的激发前FEV1%预计值(p小于0.0001)、更高的吸烟包年数(p = 0.0099)、血嗜酸性粒细胞计数(p = 0.0004)、皮肤试验反应性(p = 0.0047)以及女性性别(p = 0.0302)相关。我们得出结论,在慢性非特异性肺部疾病(CNSLD)中开展长期多中心试验是可行的,并且这些试验可能会提供有关该疾病治疗和预后的有价值信息。